Trial Profile

Clinical Phase 3 Study to Monitor the Safety, Tolerability, and Efficacy of Subcutaneous Human Immunoglobulin (CUTAQUIG) Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Aug 2023 Results published in the Journal of Clinical Immunology
23 May 2023 According to Octapharma USA media release, Sudhir Gupta, MD, Chief, Basic and Clinical Immunology, University of California, Irvine, School of Medicine, and Director, Jeffrey Modell Diagnostic Center for Primary Immunodeficiencies, is a Primary Investigator of this study.
23 May 2023 Results presented in a Octapharma media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com